PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31715421-6	2019	RET fusions or rearrangements are somatic juxtapositions of 5" sequences from other genes with 3" RET sequences encoding tyrosine kinase.	Tyrosine	121-129	ret proto-oncogene	Homo sapiens	0-3	
31715421-6	2019	RET fusions or rearrangements are somatic juxtapositions of 5" sequences from other genes with 3" RET sequences encoding tyrosine kinase.	Tyrosine	121-129	ret proto-oncogene	Homo sapiens	98-101	
31715421-9	2019	Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease.	Tyrosine	0-8	ret proto-oncogene	Homo sapiens	65-68	
31715421-9	2019	Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease.	Tyrosine	0-8	ret proto-oncogene	Homo sapiens	72-75	
31715421-9	2019	Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease.	Tyrosine	0-8	ret proto-oncogene	Homo sapiens	72-75	
31715421-9	2019	Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease.	Tyrosine	0-8	ret proto-oncogene	Homo sapiens	72-75	
31715421-13	2019	RET fusions provide a viable therapeutic target for oncologic treatment, and further study is warranted into the prevalence and pathogenesis of RET fusions as well as development of current and new tyrosine kinase inhibitors.	Tyrosine	198-206	ret proto-oncogene	Homo sapiens	0-3